$NTRA

ROSENMAN HERM sold $4.1M of NTRA

ROSENMAN HERM sold 16,530 shares of Natera, Inc. (NTRA) at $250.00 ($4.13M total) on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROSENMAN HERM
Published Jun 27, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 27, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed sale is a director open-market transaction executed under a pre-arranged 10b5-1 plan, which typically limits inference about management’s forward outlook.

02

Market read

This provides incremental insider-activity information but no new operational, financial, or regulatory catalyst.

03

What to watch

Traders may over-weight the sale size; without additional context (e.g., total insider holdings trend, other concurrent filings), the signal is weak.

Relevance 5/10Novelty 4/10Timing: latest Form 4 filed late June; sale dated 2026-06-24

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera (NTRA) disclosed a director open-market sale of 16,530 shares at $250/share under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about sentiment/positioning than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which generally dampens interpretability versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than a view on near-term prospects.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider transaction; director sold 16,530 shares at $250/share.

  • ROSENMAN HERM

    Director who reported the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.